Literature DB >> 3947379

Fate of an antibody-ricin A chain conjugate administered to normal rats.

N R Worrell, A J Cumber, G D Parnell, W C Ross, J A Forrester.   

Abstract

The pharmacokinetics and catabolism of ricin A chain, a mouse monoclonal antibody (LICR-LOND-Fib 75) and a disulphide linked conjugate of the two have been studied following their intravenous administration to normal rats. Results indicate that the conjugate was removed from the circulation much more rapidly than the antibody but less quickly than the free ricin A chain. Disappearance of the conjugate from the circulation appeared to be biphasic with an early rapid initial phase followed by a much more rapidly than the antibody but less quickly than the free ricin A chain. Disappearance of the conjugate from the circulation appeared to be biphasic with an early rapid initial phase followed by a much slower phase. The fate of a conjugate with a 125I iodide label in the antibody component was compared with that of a conjugate similarly labelled but in the ricin A chain component. The results indicate that breakdown of the conjugate involves both cleavage of the disulphide linkage and complete catabolism of the whole conjugate molecule with the release of 125I iodide. Rapid cleavage of the disulphide bond in the vasculature does not appear to be responsible for the initial rapid disappearance of the conjugate from the circulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947379     DOI: 10.1016/0006-2952(86)90214-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Disposition and tumor localization of mitomycin C-dextran conjugates in mice.

Authors:  Y Takakura; A Takagi; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1987-08       Impact factor: 4.200

3.  Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.

Authors:  L Cattel; L Delprino; P Brusa; F Dosio; P M Comoglio; M Prat
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.

Authors:  P Brusa; F Pietribiasi; G Bussolati; F Dosio; R Arione; P M Comoglio; M Prat; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.

Authors:  R G Melton; F Searle; R F Sherwood; K D Bagshawe; J A Boden
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

6.  Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate.

Authors:  A Noguchi; T Takahashi; T Yamaguchi; K Kitamura; Y Takakura; M Hashida; H Sezaki
Journal:  Jpn J Cancer Res       Date:  1991-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.